These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10417009)

  • 1. Pharmaceutical use by U.S. astronauts on space shuttle missions.
    Putcha L; Berens KL; Marshburn TH; Ortega HJ; Billica RD
    Aviat Space Environ Med; 1999 Jul; 70(7):705-8. PubMed ID: 10417009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment efficacy of intramuscular promethazine for space motion sickness.
    Davis JR; Jennings RT; Beck BG; Bagian JP
    Aviat Space Environ Med; 1993 Mar; 64(3 Pt 1):230-3. PubMed ID: 8447805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of treatment strategies for Space Motion Sickness.
    Davis JR; Jennings RT; Beck BG
    Microgravity Q; 1992 Jul; 2(3):173-7. PubMed ID: 11541442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpersonal issues in space: Shuttle/Mir and beyond.
    Kanas N
    Aviat Space Environ Med; 2005 Jun; 76(6 Suppl):B126-34. PubMed ID: 15943205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sudden emesis following parabolic flight maneuvers: implications for space motion sickness.
    Lackner JR; Graybiel A
    Aviat Space Environ Med; 1986 Apr; 57(4):343-7. PubMed ID: 3485969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid function changes related to use of iodinated water in the U.S. Space Program.
    McMonigal KA; Braverman LE; Dunn JT; Stanbury JB; Wear ML; Hamm PB; Sauer RL; Billica RD; Pool SL
    Aviat Space Environ Med; 2000 Nov; 71(11):1120-5. PubMed ID: 11086666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. McGill-trained MD, experiment give June 20 shuttle flight strong Canadian flavour.
    Thirsk R
    CMAJ; 1996 Jun; 154(12):1884-8. PubMed ID: 8653649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial issues in space: results from Shuttle/Mir.
    Kanas N; Salnitskiy V; Grund EM; Weiss DS; Gushin V; Bostrom A; Kozerenko O; Sled A; Marmar CR
    Gravit Space Biol Bull; 2001 Jun; 14(2):35-45. PubMed ID: 11865867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in neutrophil functions in astronauts.
    Kaur I; Simons ER; Castro VA; Mark Ott C; Pierson DL
    Brain Behav Immun; 2004 Sep; 18(5):443-50. PubMed ID: 15265537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute urinary retention among astronauts.
    Stepaniak PC; Ramchandani SR; Jones JA
    Aviat Space Environ Med; 2007 Apr; 78(4 Suppl):A5-8. PubMed ID: 17511293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of drug countermeasures for space motion sickness on working memory in humans.
    Paule MG; Chelonis JJ; Blake DJ; Dornhoffer JL
    Neurotoxicol Teratol; 2004; 26(6):825-37. PubMed ID: 15451046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promethazine as a motion sickness treatment: impact on human performance and mood states.
    Cowings PS; Toscano WB; DeRoshia C; Miller NE
    Aviat Space Environ Med; 2000 Oct; 71(10):1013-22. PubMed ID: 11051308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus shedding by astronauts during space flight.
    Pierson DL; Stowe RP; Phillips TM; Lugg DJ; Mehta SK
    Brain Behav Immun; 2005 May; 19(3):235-42. PubMed ID: 15797312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic considerations for Shuttle astronauts.
    Santy PA; Bungo MW
    J Clin Pharmacol; 1991 Oct; 31(10):931-3. PubMed ID: 1761724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of space sickness in shuttle-orbiter missions.
    Graybiel A
    Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group interactions during space missions.
    Kanas N
    Aviat Space Environ Med; 2004 Jul; 75(7 Suppl):C3-5. PubMed ID: 15267068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological, pharmacokinetic, and pharmacodynamic changes in space.
    Graebe A; Schuck EL; Lensing P; Putcha L; Derendorf H
    J Clin Pharmacol; 2004 Aug; 44(8):837-53. PubMed ID: 15286087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of chromosome aberration frequencies in pre- and post-flight astronaut lymphocytes irradiated in vitro with gamma rays.
    Wu H; George K; Willingham V; Cucinotta FA
    Phys Med; 2001; 17 Suppl 1():229-31. PubMed ID: 11776983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of medicaments in space--therapeutic measures and potential impact of pharmacokinetics due to weightlessness.
    Pavy-Le Traon A; Guell A; Saivin S; Houin G; Soulez-Lariviere C; Pujos M
    ESA J; 1994; 18(1):33-50. PubMed ID: 11541451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NASA study of cataract in astronauts (NASCA). Report 1: Cross-sectional study of the relationship of exposure to space radiation and risk of lens opacity.
    Chylack LT; Peterson LE; Feiveson AH; Wear ML; Manuel FK; Tung WH; Hardy DS; Marak LJ; Cucinotta FA
    Radiat Res; 2009 Jul; 172(1):10-20. PubMed ID: 19580503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.